Posted by Michael Wonder on 21 Apr 2019
Moleculin receives FDA approval of fast track designation for annamycin
18 April 2019 - Moleculin Biotech today announced that the U.S. FDA has approved its request for fast track designation for its drug, annamycin for the treatment of relapsed or refractory acute myeloid leukaemia.
Currently, annamycin is in separate Phase I/II trials in the U.S. and Europe for the treatment of acute myeloid leukaemia and the Company has recently announced positive interim top line data.
